Effect of HMG CoA Reductase Inhibitors (Statins) in Hyperadrenocorticism with Hyperlipidemia Dog: A Case Report
Secondary disorders of dyslipoprotein metabolism are associated with endocrinopathy including hyperadrenocorticism, hypothyroidism and diabetes mellitus. The clinical manifestations of hyperlipidemia are unpredictable. The most common sign is xanthoma formation, lipemia retinalis. Atherosclerosis was reported in hyperlipidemia in dogs. The proposed is reported effective of HMG CoA reductase inhibitors (statins) for the management of hyperlipidemia in hyperadrenocorticism in dog.
A 7-year-old male Bichon was diagnosed with hyperadrenocorticism (PDH) and had been treated with trilostane 2 mg/kg once a day for 1 year. All clinical signs were acceptable in good appetite, mild improvement in polyuria and polydipsia, and mild pot belly was detected. His cornea was clear and no evidence of lipemia retinalis. He showed mild hypertension (SBP 170 mm Hg), high cholesterol (10.86 mmol/L) and high triglyceride (4.86 mmol/L). He was provided a simvastatin dose 20 mg/d every other day for 2 months.
There were reduced serum cholesterol (8.66 mmol/L), serum triglyceride (1.76 mmol/L) and LDL (9) without other clinical side effects. The dog had a good response and improvement in cholesterol corneal deposit.